
Biohaven Pharmaceutical Holding Company Ltd. BHVN
$ 12.36
-9.65%
Biohaven Pharmaceutical Holding Company Ltd. Total Assets | BHVN
Total Assets — these are all the resources owned by the business that have economic value. They are used to operate the business, generate profit, and ensure the company’s stability.Main categories of assets
Current assets (used within one year):
- Cash and cash equivalents
- Accounts receivable (amounts owed by customers)
- Inventory of goods, raw materials, and supplies
- Short-term investments
- Fixed assets (buildings, machinery, equipment)
- Intangible assets (brands, patents, software)
- Long-term investments
- Goodwill (reputational value from mergers)
Assets represent an objective measure of a business's value, reflecting everything behind it: physical infrastructure, technology, customer base, and financial resources. A high share of liquid assets such as cash indicates a company’s financial flexibility and its ability to maintain stability in changing market conditions.
Asset analysis helps assess how effectively a company utilizes its resources to generate revenue and profit, reflecting its operational efficiency and ability to convert invested capital into financial results.
Annual Total Assets Biohaven Pharmaceutical Holding Company Ltd.
| 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 |
|---|---|---|---|---|---|---|---|---|---|---|
| 1.08 B | 687 M | 344 M | 290 M | 147 M | 27 M | 1.89 M | - | - | - | - |
Annual performance
Select metrics to display
All numbers in USD currency
Indicator range from annual reports
| Maximum | Minimum | Average |
|---|---|---|
| 1.08 B | 1.89 M | 368 M |
Quarterly Total Assets Biohaven Pharmaceutical Holding Company Ltd.
| 2022-Q4 | 2022-Q3 | 2022-Q2 | 2022-Q1 | 2021-Q4 | 2021-Q3 | 2021-Q2 | 2021-Q1 | 2020-Q4 | 2020-Q3 | 2020-Q2 | 2020-Q1 | 2019-Q4 | 2019-Q3 | 2019-Q2 | 2019-Q1 | 2018-Q4 | 2018-Q3 | 2018-Q2 | 2018-Q1 | 2017-Q4 | 2017-Q3 | 2017-Q2 | 2017-Q1 | 2016-Q4 | 2016-Q3 | 2016-Q2 | 2016-Q1 | 2015-Q4 | 2015-Q3 | 2015-Q2 | 2015-Q1 | 2014-Q4 | 2014-Q3 | 2014-Q2 | 2014-Q1 | 2013-Q4 | 2013-Q3 | 2013-Q2 | 2013-Q1 | 2012-Q4 | 2012-Q3 | 2012-Q2 | 2012-Q1 | 2011-Q4 | 2011-Q3 | 2011-Q2 | 2011-Q1 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| - | - | 1.39 B | 1.37 B | 1.08 B | 1.13 B | 846 M | 1 B | 687 M | 782 M | 424 M | 533 M | 344 M | 439 M | 491 M | 245 M | 290 M | 195 M | 239 M | 126 M | 147 M | 185 M | 214 M | 60.2 M | 27 M | 27 M | 27 M | 27 M | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
Quarterly performance
Select metrics to display
All numbers in USD currency
Indicator range from quarterly reporting
| Maximum | Minimum | Average |
|---|---|---|
| 1.39 B | 27 M | 474 M |
Total Assets of other stocks in the Biotechnology industry
| Issuer | Total Assets | Price | % 24h | Market Cap | Country | |
|---|---|---|---|---|---|---|
|
Lipocine
LPCN
|
17 M | $ 1.47 | -2.33 % | $ 8.01 M | ||
|
Seres Therapeutics
MCRB
|
138 M | $ 1.25 | -6.02 % | $ 11.1 M | ||
|
Oramed Pharmaceuticals
ORMP
|
231 M | $ 3.58 | -2.98 % | $ 148 M | ||
|
Madrigal Pharmaceuticals
MDGL
|
1.26 B | $ 378.19 | -4.68 % | $ 8.48 B | ||
|
CEL-SCI Corporation
CVM
|
28.2 M | $ 1.2 | -18.37 % | $ 9.62 M | ||
|
Inventiva S.A.
IVA
|
119 M | $ 3.14 | -9.13 % | $ 188 M | ||
|
MeiraGTx Holdings plc
MGTX
|
244 M | $ 7.98 | -1.97 % | $ 642 M | ||
|
Teva Pharmaceutical Industries Limited
TEVA
|
40.7 B | $ 39.21 | 1.76 % | $ 44.9 B | ||
|
Eton Pharmaceuticals
ETON
|
92.1 M | $ 60.77 | -0.96 % | $ 1.64 B | ||
|
IDEAYA Biosciences
IDYA
|
1.11 B | $ 25.52 | -2.48 % | $ 2.26 B | ||
|
Protalix BioTherapeutics
PLX
|
82.3 M | $ 2.89 | -5.56 % | $ 227 M | ||
|
Lantern Pharma
LTRN
|
11 M | $ 0.25 | -13.67 % | $ 2.72 M | ||
|
Foghorn Therapeutics
FHTX
|
198 M | $ 1.71 | -3.93 % | $ 108 M | ||
|
Ocugen
OCGN
|
43.5 M | $ 0.77 | 4.74 % | $ 241 M | ||
|
Oncolytics Biotech
ONCY
|
20.2 M | $ 0.35 | -10.37 % | $ 33.6 M | ||
|
Minerva Neurosciences
NERV
|
98 M | $ 2.03 | -4.25 % | $ 17.2 M | ||
|
Neurocrine Biosciences
NBIX
|
4.63 B | $ 150.5 | -3.89 % | $ 15 B | ||
|
Nanobiotix S.A.
NBTX
|
67.8 M | $ 26.12 | -1.7 % | $ 1.25 T | ||
|
Prothena Corporation plc
PRTA
|
327 M | $ 8.12 | -3.33 % | $ 437 M | ||
|
Mereo BioPharma Group plc
MREO
|
88.1 M | $ 0.26 | -5.45 % | $ 207 M | ||
|
Maravai LifeSciences Holdings
MRVI
|
771 M | $ 6.99 | -2.85 % | $ 1.01 B | ||
|
Lexicon Pharmaceuticals
LXRX
|
185 M | $ 1.53 | -8.68 % | $ 555 M | ||
|
Moleculin Biotech
MBRX
|
22.1 M | $ 7.73 | -2.59 % | $ 9.16 M | ||
|
Takeda Pharmaceutical Company Limited
TAK
|
14.2 T | $ 21.79 | 1.66 % | $ 34.4 B | ||
|
Nurix Therapeutics
NRIX
|
688 M | $ 12.88 | -5.29 % | $ 1.12 B | ||
|
Nkarta
NKTX
|
404 M | $ 1.14 | 1.34 % | $ 84.3 M | ||
|
MacroGenics
MGNX
|
257 M | $ 1.97 | -0.76 % | $ 124 M | ||
|
Protagonist Therapeutics
PTGX
|
668 M | $ 121.72 | -2.2 % | $ 7.74 B | ||
|
Novo Nordisk A/S
NVO
|
543 B | $ 37.8 | -2.82 % | $ 168 B | ||
|
Marker Therapeutics
MRKR
|
19.1 M | $ 1.1 | -17.05 % | $ 16.8 M | ||
|
Arcus Biosciences
RCUS
|
1.14 B | $ 15.62 | -1.01 % | $ 1.68 B | ||
|
Replimune Group
REPL
|
332 M | $ 19.07 | -0.83 % | $ 1.77 B | ||
|
NextCure
NXTC
|
22.6 M | $ 6.62 | -2.43 % | $ 35.2 M | ||
|
Rocket Pharmaceuticals
RCKT
|
330 M | $ 1.95 | -7.82 % | $ 217 M | ||
|
PMV Pharmaceuticals
PMVP
|
117 M | $ 0.87 | -33.79 % | $ 45.7 M | ||
|
United Therapeutics Corporation
UTHR
|
7.88 B | $ 553.08 | -1.08 % | $ 24.5 B | ||
|
Olema Pharmaceuticals
OLMA
|
533 M | $ 7.0 | -2.1 % | $ 609 M | ||
|
Kymera Therapeutics
KYMR
|
1.74 B | $ 115.19 | -3.52 % | $ 9.73 B | ||
|
Oragenics
OGEN
|
10.1 M | $ 0.16 | -6.16 % | $ 345 K | ||
|
Ovid Therapeutics
OVID
|
151 M | $ 2.2 | -5.98 % | $ 286 M | ||
|
Passage Bio
PASG
|
25.2 M | $ 3.94 | 9.14 % | $ 12.6 M | ||
|
Vaxcyte
PCVX
|
3 B | $ 55.37 | -5.12 % | $ 7.54 B | ||
|
Relay Therapeutics
RLAY
|
621 M | $ 16.11 | 1.26 % | $ 2.76 B | ||
|
Precigen
PGEN
|
156 M | $ 4.21 | 1.08 % | $ 1.32 B | ||
|
Avidity Biosciences
RNA
|
1.96 B | $ 6.94 | -0.57 % | $ 956 M | ||
|
Phio Pharmaceuticals Corp.
PHIO
|
21.5 M | $ 0.66 | -7.55 % | $ 3.95 M | ||
|
Praxis Precision Medicines
PRAX
|
938 M | $ 300.01 | -3.5 % | $ 6.75 B | ||
|
Prelude Therapeutics Incorporated
PRLD
|
141 M | $ 3.22 | -1.08 % | $ 248 M | ||
|
ProQR Therapeutics N.V.
PRQR
|
113 M | $ 1.02 | -2.38 % | $ 107 M | ||
|
Ocular Therapeutix
OCUL
|
808 M | $ 5.57 | -5.03 % | $ 1.04 B |